CAMP vs SRPT
CAMP: CAMP4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapies to upregulate gene expression and restore protein levels for patients with genetic diseases. SRPT: Sarepta Therapeutics is a leader in genetic medicine, specializing in innovative RNA-targeted and gene therapies to treat rare neuromuscular diseases like Duchenne muscular dystrophy.
Side-by-side fundamentals
| Metric | CAMP | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $3.70 | $18.21 | |
| Market cap | $232M | $1.9B | |
| Net margin FY2025, SEC XBRL | -2298.5% | -32.5% | SRPT higher |
| Operating margin FY2025, SEC XBRL | -1502.4% | -31.8% | SRPT higher |
| ROE FY2025, SEC XBRL | -168.5% | -62.5% | SRPT higher |
| ROA FY2025, SEC XBRL | -68.2% | -21.3% | SRPT higher |
| Debt / equity as of 2026-09-03 | 0.00 | 0.55 | CAMP lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.6% | -20.4% | CAMP higher |
| Revenue CAGR (3y) SEC XBRL | +216.1% | +33.1% | CAMP higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.48 | 1.56 | |
| 1-year return as of 2026-10-08 close | +4.5% | -22.1% | CAMP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.